Literature DB >> 954351

Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green.

R L Williams, T F Blaschke, P J Meffin, K L Melmon, M Rowland.   

Abstract

The disposition of lidocaine and indocyanine green was studied in 6 individuals during and after recovery from an episode of acute viral hepatitis. Both compounds are highly cleared from the blood by the liver so that clearance of both should be sensitive to changes in hepatic blood flow. During the acute phase of illness, clearance of indocyanine green decreased without apparent change in volume of distribution, whereas clearance of lidocaine, decreased in 4, did not change in 1, and increased in 1 during the acute phase of hepatitis. Volume changes for lidocaine were also variable. We observed no significant correlation between any parameters of lidocaine disposition and any of several tests of liver function or any parameters of indocyanine green disposition. The absence of correlation between pharmacokinetic parameters of the disposition of lidocaine and indocyanine green indicates that the influence of hepatic disease on the hepatic processes that lead to the elimination of each compound is not predictable. No useful clinical correlates are now available by means of which to predict lidocaine disposition in patients with altered hepatic function.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954351     DOI: 10.1002/cpt1976203290

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Sedation for fibreoptic bronchoscopy.

Authors:  M P Shelley; P Wilson; J Norman
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

Review 3.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

4.  Influence of phenobarbital on the disposition of clonazepam and antipyrine in the dog.

Authors:  I Bekersky; A C Maggio; V Mattaliano; H G Boxenbaum; D E Maynard; P D Cohn; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 5.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 6.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of epidural and spinal anaesthesia.

Authors:  A G Burm
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 8.  Drug prescribing in hepatobiliary disease.

Authors:  R K Roberts; P V Desmond; S Schenker
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

10.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Authors:  N D Bax; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.